A phase I/II dose-escalation study investigating all-oral ixazomib-melphalanprednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

  1. San-Miguel, J.F.
  2. Gutierrez, M.-A.E.
  3. Špicka, I.
  4. Mateos, M.-V.
  5. Song, K.
  6. Craig, M.D.
  7. Bladé, J.
  8. Hájek, R.
  9. Chen, C.
  10. Di Bacco, A.
  11. Estevam, J.
  12. Gupta, N.
  13. Byrne, C.
  14. Lu, V.
  15. Van De Velde, H.
  16. Lonial, S.
Journal:
Haematologica

ISSN: 1592-8721 0390-6078

Year of publication: 2018

Volume: 103

Issue: 9

Pages: 1518-1526

Type: Article

DOI: 10.3324/HAEMATOL.2017.185991 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals